We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Phaxiam Therapeutics SA (PHXM) EUR1

Sell:€1.98 Buy:€1.99 Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:€1.98
Buy:€1.99
Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:€1.98
Buy:€1.99
Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

PHAXIAM Therapeutics SA, formerly known as ERYTECH PHARMA SA, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The company relies on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics SA is developing a portfolio of phages targeting three of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. It offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer.

Contact details

Address:
60 avenue Rockefeller
LYON
69008
France
Telephone:
+33 (4) 78744438
Website:
https://erytech.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PHXM
ISIN:
FR001400K4B1
Market cap:
€22.05 million
Shares in issue:
11.14 million
Sector:
Biotechnology
Exchange:
Euronext Paris
Country:
France
Currency:
Euro
Indices:
n/a

Key personnel

  • Gil Beyen
    Chief Executive Officer, Director
  • Eric Soyer
    Chief Financial Officer, Chief Operating Officer, Deputy General Manager
  • Jerome Bailly
    Deputy General Manager, Operations Chief Quality Officer and Qualified Person
  • Anne-Cecile Fumey
    Human Resources Director
  • Karine Charton
    Director - Innovation and Valorization
  • Iman El-Hariry
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.